In this study, the authors conducted an in-depth analysis of the health status of patients enrolled in the TRISCEND II pivotal trial (Edwards EVOQUE Transcatheter Tricuspid Valve Replacement: Pivotal Clinical Investigation of Safety and Clinical Efficacy Using a Novel Device) to help quantify the benefit of intervention for these patients.
ALERT!
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
Transcatheter
December 12, 2024
December 12, 2024
In the TRISCEND II trial, a total of 400 patients with severe symptomatic tricuspid regurgitation were randomized in a 2:1 ratio to undergo either transcatheter tricuspid valve replacement with medical therapy (valve-replacement group) or medical therapy alone (control group).
December 5, 2024
Development of myocardial fibrosis in patients with aortic stenosis precedes left ventricular decompensation and is associated with an adverse long-term prognosis.
November 26, 2024
Neurohormonal modulation and afterload reduction are essential for treating heart failure with reduced ejection fraction (HFrEF). In HFrEF patients with concomitant moderate aortic stenosis (AS), therapy with transcatheter aortic valve replacement (TAVR) may be complementary to guideline-directed medical therapy (GDMT).
November 26, 2024
This study compared outcomes between patients undergoing valve-in-valve transcatheter aortic valve replacement (ViV TAVR) and redo surgical aortic valve replacement (redo SAVR) using a retrospective analysis of institutional databases, which included data from 2013 to 2022 for TAVR and 2011 to 2022 for SAVR.
November 26, 2024
The EARLY TAVR trial investigators randomly assigned patients with asymptomatic severe aortic stenosis to undergo either early transfemoral transcatheter aortic valve replacement (TAVR) or clinical surveillance. The primary end point was a composite of death, stroke, or unplanned hospitalization for cardiovascular causes.
November 21, 2024
CTSNet continued its webinar series partnership with the ASAIO Journal on November 14, 2024, by enrolling cardiac surgery and heart failure professionals engaged to discuss the topic, "Non-LVAD and Non-CRT Device Options in Heart Failure." Panelists included Amit N. Vora, MD, MPH, FACC, FSCAI, of Yale University, and Ulrich P. Jorde, MD, of Montefiore Health System.
November 21, 2024
In this meta-analysis, the authors included three randomized controlled trials (RCTs) conducted in patients with heart failure (HF) and moderate to severe functional mitral regurgitation (FMR), comparing treatment with the MitraClip device in addition to medical therapy (device arm) to medical therapy alone (control arm).
November 11, 2024
This video presents a clinical case of a 44-year-old man with severe respiratory failure and septic shock secondary to streptococcus pyogenes pneumonia. The authors describe a transfer technique from femoro-jugular veno-venous ECMO to veno-pulmonary ECMO with the ProtekDuo cannula.
November 7, 2024
Aortic stenosis is the most prevalent valvular heart condition necessitating surgical intervention, with full sternotomy (FS) traditionally being the standard approach for surgical aortic valve replacement (SAVR).